Press Coverage
National reporting on GLP-1 access, affordability, and patient experience.
Amanda Bonello has contributed patient and advocacy perspectives to reporting on compounded GLP-1 medications, insurance barriers, regulatory decisions, pharmaceutical policy, and continued access to obesity treatment.
Her media appearances are informed by direct patient engagement, public advocacy, and ongoing analysis of the GLP-1 industry.
Featured Coverage
Patients struggling as the compounding crackdown ended discounted access.
Reuters · May 23, 2025
Interviewed about patient access to compounded GLP-1 medications
Recent Press Coverage
The reporting, newest first.
Insurance Coverage
Fewer employers are covering GLP-1 drugs for weight loss. Should they?
Interviewed on the cost of staying on GLP-1s and safer ways to access them
Read the Article →
Affordability
New research on whether GLP-1s are worth the cost.
Background interview by phone, and connected a patient for the story
Read the Article →
GLP-1 Access
GLP-1 access in Florida.
Interviewed on GLP-1 access
Patient Experience
Exercise, weight-loss drugs, and how patients actually use GLP-1 medications.
Facilitated patient interview connections
Read the Article →
Insurance Coverage
She lost 100 pounds on Zepbound. Then her insurance cut her off.
Background interview on insurance coverage, and connected patients for interviews
Read the Article →
Pharmaceutical Policy
Novo Nordisk litigation against compounders and what patient advocates fear.
Provided patient and advocacy perspective
Read the Article →
Compounded Medications
Patients struggling as the compounding crackdown ended discounted access.
Interviewed about patient access to compounded GLP-1 medications
Read the Article →
Compounded Medications
The compounded GLP-1 landscape and medication copycats.
Provided patient perspective on medication affordability
Read the Article →
FDA and Regulation
Compounded Wegovy and Zepbound potentially disappearing under new FDA rules.
Commented on regulatory changes affecting continued treatment
Read the Article →
GLP-1 Access
The Zepbound shortage, compounding pharmacies, and patient access.
Provided patient perspective on access
Read the Article →
Affordability
High prices pushing patients toward weight-loss drug alternatives.
Provided patient perspective on medication affordability
Read the Article →
GLP-1 Access
GLP-1 patient petitions to the FDA over continued access.
Shared insight from the national access petition
Read the Article →
FDA and Regulation
Urging the FDA to support compounded GLP-1 alternatives.
Shared insight from the national access petition
Read the Article →
FDA and Regulation
FDA action on compounded weight-loss drugs and its patient impact.
Discussed regulatory changes affecting patients
Read the Article →
Public Perception
A community radio conversation on GLP-1 access and advocacy.
Shared patient and advocacy perspective
Read the Article →
Coverage of the Access Campaign
Reporting informed by more than 27,000 petition supporters.
Amanda launched a national petition calling for continued, affordable access to GLP-1 medications.
The campaign gathered more than 27,000 verified signatures and hundreds of public comments describing the effects of medication cost, insurance exclusions, and possible loss of treatment.
Journalists have used the campaign and Amanda's perspective to examine the practical consequences of regulatory and market decisions.
27,000+
Verified petition signatures
400+
Public patient comments
Federal Outreach
Patient concerns presented to the FDA and USPTO
Publications featuring Amanda's perspective.
Available for Commentary
Informed media commentary.
GLP-1 Access and Affordability
Medication costs, insurance exclusions, employer coverage, access barriers, and the consequences of interrupted treatment.
Compounded GLP-1 Medications
Patient use, affordability, pharmacy access, regulatory developments, and the effect of policy changes.
Patient Experience
Treatment expectations, stigma, communication, side effects, long-term support, and the realities of navigating obesity care.
FDA and Policy Developments
Regulatory announcements, federal decisions, pharmaceutical policy, and the patient consequences of changing requirements.
Telehealth and Patient Support
Onboarding, education, retention, communication, clinical escalation, and trust within virtual obesity care.
GLP-1 Communities
Patient sentiment, emerging concerns, misinformation, advocacy priorities, and changes in public conversation.
About Amanda Bonello
Amanda Bonello is an independent GLP-1 industry advisor, advocate, founder of GLP-1 Studio, and host of the GLP-1 Studio Podcast.
She advises organizations across patient experience, industry strategy, policy, media, research, advocacy, and obesity care.
Amanda launched a national GLP-1 access petition that has gathered more than 27,000 verified signatures and hundreds of public patient comments.
She regularly contributes patient and industry perspectives to national reporting on access, affordability, compounded medications, regulation, and obesity treatment.
Media requests
Please include:
- Publication or program
- Subject
- Interview format
- Requested date
- Deadline
- Expected publication or air date
- Contact information
For deadline-sensitive requests, include the deadline in the inquiry form.
Request Amanda's perspective for an upcoming story.
I am available for interviews, background conversations, podcast appearances, television segments, and written commentary related to GLP-1 access, obesity care, patient experience, advocacy, and industry developments.